Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease
Background: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications. Objective: To explore the relationship between national health te...
Gespeichert in:
| Veröffentlicht in: | Journal of market access & health policy 2021, Vol.9 (1), p.1929757-1929757 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1929757 |
|---|---|
| container_issue | 1 |
| container_start_page | 1929757 |
| container_title | Journal of market access & health policy |
| container_volume | 9 |
| creator | Cook, Jennifer Bloom, Chloe Lewis, Jen Marjenberg, Zoe Platz, Jaime Hernando Langham, Sue |
| description | Background: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications.
Objective: To explore the relationship between national health technology assessment (HTA) agency appraisals and market penetration of two fixed-dose combination (FDC) triple therapies.
Study design: HTAs from Q3 2017 to Q1 2020 from 10 countries were evaluated.
Intervention: Glycopyrronium bromide/formoterol fumarate/beclomethasone (Trimbow®) and umeclidinium/vilanterol/fluticasone furoate (Trelegy™ Ellipta®).
Main outcome measure: HTA restrictions and prescribing rates (days of therapy).
Results: Seven countries (70%) imposed restrictions on use including prescription only for patients stable on free-combination triple therapy or not controlled on dual therapy, requirement of a specialist prescription or therapeutic plan, prescription only for patients with severe COPD, and use as second-line therapy or later. In general, countries that have imposed restrictions on the use of FDC triple therapies have seen a lower than average uptake.
Conclusion: Payer guidance on prescribing FDC triple therapy may potentially support more appropriate prescribing in line with clinical guidelines. It is important for payers to consider which restrictions would ensure the most efficient use of scarce resources. |
| doi_str_mv | 10.1080/20016689.2021.1929757 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_20016689_2021_1929757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4d8762b3aee14aebab792d1e652fad73</doaj_id><sourcerecordid>2609166219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4547-1e28bf55fb2e0a993f90d4a12d223b386e59c256b16d33b1b6fa2c43579ef5f83</originalsourceid><addsrcrecordid>eNp9ks9u1DAQxiMEolXpIyBZ4sJlF9uJ4-SCQBV_VqrEBc7WxB5vXCV2sJ3CvgmPi5ddEOXAyeOZ7_tpNPqq6jmjW0Y7-opTytq267eccrZlPe-lkI-qy2N_cxw8_qu-qK5TuqPlWzecSvG0uqgbxrns2GX1YzcvoDMJlowIUx5JRj36MIX9gUBKmNKMvsw9WSImHd3g_J4skDNGn44-50eY0BDrvqPZmJCQ6DAXGWRXbDm6ZUKSR4ywHIqa6DEG7zQJQ8px1dndI1nWaQ4e4oEYlxASPqueWJgSXp_fq-rL-3efbz5ubj992N28vd3oRjRyw5B3gxXCDhwp9H1te2oaYNxwXg9116LoNRftwFpT1wMbWgtcN7WQPVphu_qq2p24JsCdWqKbyxIqgFO_GiHuFcTs9ISqMZ1s-VADImsABxhkzw3DVnALRtaF9frEWtZhRqPL4SJMD6APJ96Nah_uVcdk00hZAC_PgBi-rpiyml3SOE3gMaxJcdFQyWnLRJG--Ed6F9boy6kUb2lf4sFZX1TipNIxpBTR_lmGUXWMkvodJXWMkjpHqfjenHzO2xBn-BbiZFSGwxSijeC1S6r-P-Ingx7SxA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2609166219</pqid></control><display><type>article</type><title>Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease</title><source>DOAJ Directory of Open Access Journals</source><source>PAIS Index</source><source>EBSCOhost Business Source Complete</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cook, Jennifer ; Bloom, Chloe ; Lewis, Jen ; Marjenberg, Zoe ; Platz, Jaime Hernando ; Langham, Sue</creator><creatorcontrib>Cook, Jennifer ; Bloom, Chloe ; Lewis, Jen ; Marjenberg, Zoe ; Platz, Jaime Hernando ; Langham, Sue</creatorcontrib><description>Background: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications.
Objective: To explore the relationship between national health technology assessment (HTA) agency appraisals and market penetration of two fixed-dose combination (FDC) triple therapies.
Study design: HTAs from Q3 2017 to Q1 2020 from 10 countries were evaluated.
Intervention: Glycopyrronium bromide/formoterol fumarate/beclomethasone (Trimbow®) and umeclidinium/vilanterol/fluticasone furoate (Trelegy™ Ellipta®).
Main outcome measure: HTA restrictions and prescribing rates (days of therapy).
Results: Seven countries (70%) imposed restrictions on use including prescription only for patients stable on free-combination triple therapy or not controlled on dual therapy, requirement of a specialist prescription or therapeutic plan, prescription only for patients with severe COPD, and use as second-line therapy or later. In general, countries that have imposed restrictions on the use of FDC triple therapies have seen a lower than average uptake.
Conclusion: Payer guidance on prescribing FDC triple therapy may potentially support more appropriate prescribing in line with clinical guidelines. It is important for payers to consider which restrictions would ensure the most efficient use of scarce resources.</description><identifier>ISSN: 2001-6689</identifier><identifier>EISSN: 2001-6689</identifier><identifier>DOI: 10.1080/20016689.2021.1929757</identifier><identifier>PMID: 34122781</identifier><language>eng</language><publisher>Abingdon: Routledge</publisher><subject>Chronic obstructive pulmonary disease ; Disease ; fixed-dose combination ; Health care expenditures ; Health technology assessment ; Intervention ; Medical treatment ; Original ; Patients ; Technology assessment ; triple therapy</subject><ispartof>Journal of market access & health policy, 2021, Vol.9 (1), p.1929757-1929757</ispartof><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4547-1e28bf55fb2e0a993f90d4a12d223b386e59c256b16d33b1b6fa2c43579ef5f83</citedby><cites>FETCH-LOGICAL-c4547-1e28bf55fb2e0a993f90d4a12d223b386e59c256b16d33b1b6fa2c43579ef5f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174477/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174477/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,4024,27502,27866,27923,27924,27925,53791,53793,59143,59144</link.rule.ids></links><search><creatorcontrib>Cook, Jennifer</creatorcontrib><creatorcontrib>Bloom, Chloe</creatorcontrib><creatorcontrib>Lewis, Jen</creatorcontrib><creatorcontrib>Marjenberg, Zoe</creatorcontrib><creatorcontrib>Platz, Jaime Hernando</creatorcontrib><creatorcontrib>Langham, Sue</creatorcontrib><title>Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease</title><title>Journal of market access & health policy</title><description>Background: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications.
Objective: To explore the relationship between national health technology assessment (HTA) agency appraisals and market penetration of two fixed-dose combination (FDC) triple therapies.
Study design: HTAs from Q3 2017 to Q1 2020 from 10 countries were evaluated.
Intervention: Glycopyrronium bromide/formoterol fumarate/beclomethasone (Trimbow®) and umeclidinium/vilanterol/fluticasone furoate (Trelegy™ Ellipta®).
Main outcome measure: HTA restrictions and prescribing rates (days of therapy).
Results: Seven countries (70%) imposed restrictions on use including prescription only for patients stable on free-combination triple therapy or not controlled on dual therapy, requirement of a specialist prescription or therapeutic plan, prescription only for patients with severe COPD, and use as second-line therapy or later. In general, countries that have imposed restrictions on the use of FDC triple therapies have seen a lower than average uptake.
Conclusion: Payer guidance on prescribing FDC triple therapy may potentially support more appropriate prescribing in line with clinical guidelines. It is important for payers to consider which restrictions would ensure the most efficient use of scarce resources.</description><subject>Chronic obstructive pulmonary disease</subject><subject>Disease</subject><subject>fixed-dose combination</subject><subject>Health care expenditures</subject><subject>Health technology assessment</subject><subject>Intervention</subject><subject>Medical treatment</subject><subject>Original</subject><subject>Patients</subject><subject>Technology assessment</subject><subject>triple therapy</subject><issn>2001-6689</issn><issn>2001-6689</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>7TQ</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks9u1DAQxiMEolXpIyBZ4sJlF9uJ4-SCQBV_VqrEBc7WxB5vXCV2sJ3CvgmPi5ddEOXAyeOZ7_tpNPqq6jmjW0Y7-opTytq267eccrZlPe-lkI-qy2N_cxw8_qu-qK5TuqPlWzecSvG0uqgbxrns2GX1YzcvoDMJlowIUx5JRj36MIX9gUBKmNKMvsw9WSImHd3g_J4skDNGn44-50eY0BDrvqPZmJCQ6DAXGWRXbDm6ZUKSR4ywHIqa6DEG7zQJQ8px1dndI1nWaQ4e4oEYlxASPqueWJgSXp_fq-rL-3efbz5ubj992N28vd3oRjRyw5B3gxXCDhwp9H1te2oaYNxwXg9116LoNRftwFpT1wMbWgtcN7WQPVphu_qq2p24JsCdWqKbyxIqgFO_GiHuFcTs9ISqMZ1s-VADImsABxhkzw3DVnALRtaF9frEWtZhRqPL4SJMD6APJ96Nah_uVcdk00hZAC_PgBi-rpiyml3SOE3gMaxJcdFQyWnLRJG--Ed6F9boy6kUb2lf4sFZX1TipNIxpBTR_lmGUXWMkvodJXWMkjpHqfjenHzO2xBn-BbiZFSGwxSijeC1S6r-P-Ingx7SxA</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Cook, Jennifer</creator><creator>Bloom, Chloe</creator><creator>Lewis, Jen</creator><creator>Marjenberg, Zoe</creator><creator>Platz, Jaime Hernando</creator><creator>Langham, Sue</creator><general>Routledge</general><general>Taylor & Francis Ltd</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TQ</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DHY</scope><scope>DON</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M0T</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2021</creationdate><title>Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease</title><author>Cook, Jennifer ; Bloom, Chloe ; Lewis, Jen ; Marjenberg, Zoe ; Platz, Jaime Hernando ; Langham, Sue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4547-1e28bf55fb2e0a993f90d4a12d223b386e59c256b16d33b1b6fa2c43579ef5f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Chronic obstructive pulmonary disease</topic><topic>Disease</topic><topic>fixed-dose combination</topic><topic>Health care expenditures</topic><topic>Health technology assessment</topic><topic>Intervention</topic><topic>Medical treatment</topic><topic>Original</topic><topic>Patients</topic><topic>Technology assessment</topic><topic>triple therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cook, Jennifer</creatorcontrib><creatorcontrib>Bloom, Chloe</creatorcontrib><creatorcontrib>Lewis, Jen</creatorcontrib><creatorcontrib>Marjenberg, Zoe</creatorcontrib><creatorcontrib>Platz, Jaime Hernando</creatorcontrib><creatorcontrib>Langham, Sue</creatorcontrib><collection>Access via Taylor & Francis (Open Access Collection)</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>PAIS Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of market access & health policy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cook, Jennifer</au><au>Bloom, Chloe</au><au>Lewis, Jen</au><au>Marjenberg, Zoe</au><au>Platz, Jaime Hernando</au><au>Langham, Sue</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease</atitle><jtitle>Journal of market access & health policy</jtitle><date>2021</date><risdate>2021</risdate><volume>9</volume><issue>1</issue><spage>1929757</spage><epage>1929757</epage><pages>1929757-1929757</pages><issn>2001-6689</issn><eissn>2001-6689</eissn><abstract>Background: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications.
Objective: To explore the relationship between national health technology assessment (HTA) agency appraisals and market penetration of two fixed-dose combination (FDC) triple therapies.
Study design: HTAs from Q3 2017 to Q1 2020 from 10 countries were evaluated.
Intervention: Glycopyrronium bromide/formoterol fumarate/beclomethasone (Trimbow®) and umeclidinium/vilanterol/fluticasone furoate (Trelegy™ Ellipta®).
Main outcome measure: HTA restrictions and prescribing rates (days of therapy).
Results: Seven countries (70%) imposed restrictions on use including prescription only for patients stable on free-combination triple therapy or not controlled on dual therapy, requirement of a specialist prescription or therapeutic plan, prescription only for patients with severe COPD, and use as second-line therapy or later. In general, countries that have imposed restrictions on the use of FDC triple therapies have seen a lower than average uptake.
Conclusion: Payer guidance on prescribing FDC triple therapy may potentially support more appropriate prescribing in line with clinical guidelines. It is important for payers to consider which restrictions would ensure the most efficient use of scarce resources.</abstract><cop>Abingdon</cop><pub>Routledge</pub><pmid>34122781</pmid><doi>10.1080/20016689.2021.1929757</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2001-6689 |
| ispartof | Journal of market access & health policy, 2021, Vol.9 (1), p.1929757-1929757 |
| issn | 2001-6689 2001-6689 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_20016689_2021_1929757 |
| source | DOAJ Directory of Open Access Journals; PAIS Index; EBSCOhost Business Source Complete; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Chronic obstructive pulmonary disease Disease fixed-dose combination Health care expenditures Health technology assessment Intervention Medical treatment Original Patients Technology assessment triple therapy |
| title | Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T22%3A24%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20health%20technology%20assessment%20on%20prescribing%20patterns%20of%20inhaled%20fixed-dose%20combination%20triple%20therapy%20in%20chronic%20obstructive%20pulmonary%20disease&rft.jtitle=Journal%20of%20market%20access%20&%20health%20policy&rft.au=Cook,%20Jennifer&rft.date=2021&rft.volume=9&rft.issue=1&rft.spage=1929757&rft.epage=1929757&rft.pages=1929757-1929757&rft.issn=2001-6689&rft.eissn=2001-6689&rft_id=info:doi/10.1080/20016689.2021.1929757&rft_dat=%3Cproquest_cross%3E2609166219%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2609166219&rft_id=info:pmid/34122781&rft_doaj_id=oai_doaj_org_article_4d8762b3aee14aebab792d1e652fad73&rfr_iscdi=true |